(KVUE) Kenvue - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US49177J1025

KVUE: Health, Beauty, Care, Medicine, Skin, Hair

Kenvue Inc. (NYSE:KVUE) is a global consumer health powerhouse, spun out from Johnson & Johnson in 2022. The company operates through three distinct segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care division is a market leader in over-the-counter (OTC) medications, offering trusted brands like Tylenol, Motrin, and Zyrtec, which dominate the cough, cold, allergy, and pain relief categories. This segment also includes nicotine cessation products under Nicorette and digestive health solutions like Imodium, catering to everyday health needs.

The Skin Health and Beauty segment boasts a robust portfolio of personal care brands, including Neutrogena, Aveeno, and Dr. Ci:Labo. These brands are recognized for their dermatologically tested products, ranging from face and body care to sun and hair products. This division capitalizes on the growing demand for science-backed, premium skincare and beauty products, positioning Kenvue as a key player in the $500 billion global beauty and personal care market.

The Essential Health segment focuses on daily wellness and hygiene products, featuring iconic brands like Listerine, Johnsons, and Band-Aid. This division also includes baby care, womens health, and wound care products, such as Johnsons baby lotions and ointments, as well as feminine hygiene products under Stayfree and Carefree. These offerings are staples in millions of households, providing steady cash flows and brand loyalty.

From a financial perspective, Kenvue trades on the NYSE under the ticker KVUE, with a market capitalization of ~$38 billion. The stock currently carries a trailing P/E of 36.67 and a forward P/E of 16.37, reflecting expectations of future earnings growth. Its price-to-book ratio of 3.57 and price-to-sales ratio of 2.46 indicate a premium valuation, consistent with its strong brand portfolio and market position. Headquartered in Skillman, New Jersey, Kenvue is well-positioned to leverage its heritage as a J&J spin-off, combining a legacy of innovation with the agility of a standalone company. For more information, visit their website at https://www.kenvue.com.

Additional Sources for KVUE Stock

KVUE Stock Overview

Market Cap in USD 44,761m
Sector Consumer Defensive
Industry Household & Personal Products
GiC Sub-Industry Personal Care Products
IPO / Inception 2023-05-04

KVUE Stock Ratings

Growth 5y 2.53%
Fundamental 13.0%
Dividend 62.9%
Rel. Strength Industry 9.2
Analysts 3.53/5
Fair Price Momentum 22.39 USD
Fair Price DCF 16.14 USD

KVUE Dividends

Dividend Yield 12m 3.72%
Yield on Cost 5y 3.24%
Annual Growth 5y 42.30%
Payout Consistency 100.0%

KVUE Growth Ratios

Growth Correlation 3m 44.8%
Growth Correlation 12m 68.3%
Growth Correlation 5y -0.9%
CAGR 5y -5.08%
CAGR/Max DD 5y -0.15
Sharpe Ratio 12m -0.55
Alpha 12.79
Beta 0.18
Volatility 27.45%
Current Volume 15798.9k
Average Volume 20d 16116.4k
What is the price of KVUE stocks?
As of March 15, 2025, the stock is trading at USD 22.81 with a total of 15,798,911 shares traded.
Over the past week, the price has changed by -2.60%, over one month by +4.01%, over three months by +4.38% and over the past year by +18.14%.
Is Kenvue a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Kenvue is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 13.04 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KVUE as of March 2025 is 22.39. This means that KVUE is currently overvalued and has a potential downside of -1.84%.
Is KVUE a buy, sell or hold?
Kenvue has received a consensus analysts rating of 3.53. Therefor, it is recommend to hold KVUE.
  • Strong Buy: 3
  • Buy: 3
  • Hold: 11
  • Sell: 0
  • Strong Sell: 0
What are the forecast for KVUE stock price target?
According to ValueRays Forecast Model, KVUE Kenvue will be worth about 24.2 in March 2026. The stock is currently trading at 22.81. This means that the stock has a potential upside of +6.01%.
Issuer Forecast Upside
Wallstreet Target Price 23.8 4.3%
Analysts Target Price 25 9.5%
ValueRay Target Price 24.2 6%